The present invention relates to a kind of ivabradine and its pharmaceutically acceptable salts sustained-release preparation, which contain ivabradine or its pharmaceutically acceptable salt and sustained release matrix material, the sustained release matrix material selected from polyoxyethylene, polyvinyl acetate and polyvinyl pyrrolidone polymer in one or several mixtures. The invention of ivabradine and its pharmaceutically acceptable salts sustained-release preparation can reduce plasma concentrations of peak valley phenomenon, so as to improve drug efficacy, drug safety, reduce the times of taking medicine to improve patient compliance.本發明涉及一種伊伐佈雷定及其可藥用鹽的緩釋製劑,其含有伊伐佈雷定或其可藥用鹽和緩釋骨架材料,該緩釋骨架材料選自聚氧乙烯、聚醋酸乙烯酯和聚乙烯吡咯烷酮聚合物中的一種或幾種的混合物。本發明的伊伐佈雷定及其可藥用鹽的緩釋製劑可以降低血中藥物濃度的峰谷現象,從而提高藥物療效、用藥安全性,減少服藥次數從而提高患者順應性。
